Class / Patent application number | Description | Number of patent applications / Date published |
514706000 | Sulfur, selenium or tellurium compound (e.g., thioalcohols, mercaptans, etc.) | 38 |
20080249185 | Physiologically active agents containing vicinal dithioglycols and use thereof in various branches of economy - The invention relates to the food and medical industries, medical cosmetics, dermatology, agriculture and the mixed feed industry. According to the invention vicinal dithioglycole (common formula RCH(SH)CH(SH)R | 10-09-2008 |
20090306219 | TOPICAL USE OF PLANT EXTRACT FOR SKIN DETOXIFICATION - Specific plant extracts are applied topically to upregulate genes which code for proteins to prevent the build-up of and mitigate the activity of various harmful materials within the skin. These upregulated proteins include glutathione transferases, peroxiredoxins, oxidoreductases, glutaredoxins and glutathione syntheses. These proteins produce additional glutathione, glyoxalase I, maintain cellular redox homeostasis, reduce hydrogen peroxide and alkylhydroperoxides, and conjugate glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles. Keratinocytes have been induced to significantly upregulate glutathione and glyoxalase I protein expression. Additionally, keratinocytes pre-treated with diallyl trisulfide have increased viability when exposed to ozone, UV radiation or cigarette smoke extract. The active material can be extracted from plants such as garlic, onions, shallots, leeks, chives, scallions, brussel sprouts, broccoli, cabbage, cauliflower, bok choy, kale, mustard, turnip or radish, may include any compound of the allyl sulfide family, and may be of synthetic origin. | 12-10-2009 |
20100035998 | COMBINATION S-NITROSOTHIOL PHARMACEUTICAL PRODUCTS FOR RESTORING NORMAL BREATHING RHYTHMS - The present invention is directed to a method of treating a lack of normal breathing control including the treatment of apnea and hypoventilation associated with sleep, obesity, certain medicines and other medical conditions. In an aspect, the invention is directed to treating disordered control of breathing by administering an composition comprising a combination of two or more compounds, at least one of which treats lack of normal breathing. In one aspect, a compound is an S-nitrosylating agent. | 02-11-2010 |
20100048730 | SULFOPEROXYCARBOXYLIC ACIDS, THEIR PREPARATION AND METHODS OF USE AS BLEACHING AND ANTIMICROBIAL AGENTS - The present invention relates to novel sulfoperoxycarboxylic acid compounds, and methods for making and using them. The sulfoperoxycarboxylic compounds of the invention are storage stable, water soluble and have low to no odor. Further, the compounds of the present invention can be formed from non-petroleum based renewable materials. The compounds of the present invention can be used as antimicrobials, and bleaching agents. The compounds of the present invention are also suitable for use as coupling agents. | 02-25-2010 |
20100197802 | SKIN DRESSINGS - Improvements relating to skin dressing A skin dressing adapted, on activation, to generate one or more S-nitrosothiols by reaction between a thiol and a nitrate salt in the dressing, the skin dressing comprising a source of Cu | 08-05-2010 |
514707000 | Persulfide (e.g., R-S-S-R, etc.) | 9 |
20080214678 | Biopesticide Comprising a Composition Rich in Diallyl Polysulphides - The present invention relates to compounds based on diallyl polysulfides, and to biopesticides comprising said compositions. The invention also relates to the use of biopesticides based on said compositions rich in diallyl polysulfides for the effective insecticidal activity thereof in relation to a large number of insects. | 09-04-2008 |
20080234388 | Integrin Modulators and Methods for their Use - 1,5-Dithiaocta-2,7-diene-5-oxide-1-yl (DODOyl) compounds and derivatives thereof, referred to collectively as DODOyl-derived compounds (DDCs), and chiral enantiomers and derivatives thereof, are described, which are integrin modulators that modulate integrin-mediated functions and/or processes. Pharmaceutical compositions containing integrin modulators and chiral enantiomers thereof, and methods for using integrin modulators and chiral enantiomers thereof are further described. | 09-25-2008 |
20080249186 | Fungicidal Composition - A fungicidal preparation comprising:
| 10-09-2008 |
20090275667 | USE OF ALLICIN AS PRESERVATIVE, AS DISINFECTANT, AS ANTIMICROBIAL OR AS BIOCIDAL AGENT - The present invention provides the use of allicin in (i) the treatment of leishmanimis; (b) as a disinfectant or biocidal treatment of aquatic species; (iii) as an antimicrobial agent for animal feed; (iv) as a preservative agent in foodstuffs; (v) as a water disinfectant or biocide; (vi) as an antiparasitic treatment or antibacterial treatment for bees (apis); or (vii) in the preparation of a medicament for the treatment of Glycopeptide Intermediate Resistant | 11-05-2009 |
20100204337 | ANTIBACTERIAL S-HETEROSUBSTITUTED DISULFIDES - Synthetically-derived S,S-heterodisubstituted disulfides that exhibit potent in vitro antibacterial activity against a variety of bacteria, including | 08-12-2010 |
20110319496 | PROCESS FOR THE PREPARATION OF AJOENE - A process for the preparation of ajoene, and of ajoene having a relatively high purity which may be obtained by the process. This invention also relates to processes for the preparation of allicin, and to a process for freeze concentrating allicin. | 12-29-2011 |
20140107222 | TREATMENTS FOR SOCIAL LEARNING DISORDERS - The use of Pak1 inhibitors to treat social or learning disabilities is disclosed. In one embodiment patients exhibiting social or learning disabilities as well as abnormally low NF1 activity are administered PAK inhibitors to treat the social or learning disabilities. Reductions in PAK activity have been found to ameliorate the effects of aberrant neurofibromatosis type 1 activity. | 04-17-2014 |
20150094381 | USE OF PROPYL PROPANE THIOSULFINATE AND PROPYL PROPANE THIOSULFONATE FOR THE PREVENTION AND REDUCTION OF PARASITES IN AQUATIC ANIMALS - A method for reducing parasites in aquatic animals is provided. The method includes reducing a plurality of parasites infecting an aquatic animal by administrating to the aquatic animal a compound comprising propyl propane thiosulfonate (PTSO) having the formula R—SOa-S—R, where R represents n-propyl group (—CH | 04-02-2015 |
20150290143 | DIMETHYL TRISULFIDE AS A CYANIDE ANTIDOTE - Dimethyl trisulfide (DMTS) antidote compositions may be used to as a cyanide poisoning antidote. | 10-15-2015 |
514708000 | Oxygen bonded directly to sulfur (e.g., sulfoxides, etc.) | 20 |
20090036541 | Applicator and chemical combination for better topical anesthesia - One embodiment of a thin plastic applicator ( | 02-05-2009 |
20100113609 | METHODS AND COMPOSITIONS FOR MALARIA PROPHYLAXIS - A composition for preventing malaria infection including a protease inhibitor. A pharmaceutical composition for preventing malaria infection including a protease inhibitor and a pharmaceutical carrier. A method of malaria infection prophylaxis including the step of administering an effective amount of the composition of the present invention. A method of malaria prophylaxis by inhibiting circumsporozoite protein processing or by inhibiting a protease of a sporozoite. Methods of preventing sporozoite cell invasion or preventing circumsporozoite processing. | 05-06-2010 |
20130253069 | Use of DMSO for Destroying Adipocytes and Eliminating Cellulite and Adiposities - The invention relates to the use of DMSO for destroying adipocytes and eliminating cellulite and adiposities, more particularly to the concentrations used for destroying adipocytes (fat cells) and eliminating cellulite and adiposities, in both males and females, resulting in the destruction of adipocytes, or fat cells, and the elimination of fat cells, which, in turn, are affected by rancidity and contain toxins, that is, rancid, fat-containing cells generate cellulite since said cells sustain cellulitic nodules, which, in turn, are observed externally as the “orange peel” effect, which is more common in women and easily identified according to the degree of cellulite, and thus, by eliminating fat cells, adiposity is naturally reduced, and consequently, there is a decrease in localized body fat. | 09-26-2013 |
20160038439 | Use of 7-a-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-estra-1,3,5(10)- triene-3,17B-diol and derivatives thereof - The present invention provides the use of a compound of Formula A for the manufacture of a medicament in the treatment of tumor necrosis factor (TNF)-related diseases, and a method for treating a TNF-related disease, said method comprising administering to a subject in need a therapeutically effective amount of a compound of Formula A. | 02-11-2016 |
514709000 | Plural oxygens bonded directly to the same sulfur (e.g., sulfones, etc.) | 16 |
20080269350 | ST104P, AN ANTI-ANGIOGENIC AGENT - The present invention relates to a method of treating a non-tumor condition or disease associated with angiogenesis in a human or animal comprises administering thereto an effective angiogenesis inhibiting dose of a tetrameric cyclic compound of 4,5-dihydroxynaphthalene-2,7, disulfonic acid linked by methylene bridges in a pharmaceutically acceptable carrier. | 10-30-2008 |
20090131536 | Treating or Preventing Renal Cancer Using a Dimethane Sulfonate - The present invention features methods of treating renal cancer by administration of certain dimethylsulfonate compounds. The present invention further features administration protocols and dosing schedules for methods of treating patients suffering from renal cancer and pharmaceutical compositions suitable for use in the treatment methods provided herein. | 05-21-2009 |
20100144890 | USE OF A SURFACTANT FOR THE PREPARATION OF A FORMULATION FOR THE TREATMENT OF ADIPOSE DISEASES - Use of a mixture comprising at least one non-aromatic surfactant having a plurality of ether and/or ester groups and at least one carrier agent for the preparation of a formulation for the treatment of adipose tissue disease and/or condition with improved bioavailability and lipolysis behaviour. | 06-10-2010 |
20100227937 | ANTIMICROBIAL ADHESIVE SYSTEM - An adhesive composition having dispersed therein a broad spectrum antimicrobial agent for use in medical applications, such as an adhesive for surgical drapes, wound dressings and tapes, is provided. The adhesive is composed of acrylic polymers, tackifiers and a preferred antimicrobial agent, diiodomethyl-p-tolylsulfone. The subject adhesive composition may be formulated as either an essentially solventless hot melt, or as a solvent based system wherein an emulsion of the antimicrobial agent and the removal of excess solvent is avoided. | 09-09-2010 |
20110190400 | Novel Compounds for Treatment of Malignant Tumors - The present invention comprises compounds, compositions and methods of use for sensitizing cancer cells, tumors, neoplasms, and malignancies to the effects of ionizing radiation used in the treatment of cancer. The invention further comprises a method of identifying novel radiosensitizing compounds. | 08-04-2011 |
20120083536 | ANTIMICROBIAL ADHESIVE SYSTEM - An adhesive composition having dispersed therein a broad spectrum antimicrobial agent for use in medical applications, such as an adhesive for surgical drapes, wound dressings and tapes, is provided. The adhesive is composed of acrylic polymers, tackifiers and a preferred antimicrobial agent, diiodomethyl-p-tolylsulfone. The subject adhesive composition may be formulated as either an essentially solventless hot melt, or as a solvent based system wherein an emulsion of the antimicrobial agent and the removal of excess solvent is avoided. | 04-05-2012 |
20130237611 | AQUEOUS FORMULATIONS OF (2-HYDROXYMETHYL-INDANYL-4-OXY)-PHENYL-4,4,4-TRIFLUOROBUTANE-1-SULFONATE - The invention relates to aqueous formulations containing (−)-(R)-3-(2-hydroxymethylindanyl-4-oxy)phenyl 4,4,4-trifluorobutane-1-sulfonate. Said formulations are suitable as infusion solutions or as concentrate for producing these infusion solutions. | 09-12-2013 |
20150065584 | Methods Of Use For 2,5-Dihydroxybenzene Sulfonic Acid Compounds For The Treatment Of Cancer, Rosacea And Psoriasis - The invention describes compositions and methods of use for 2,5-dihydroxybenzene sulfonic acid compounds and pharmaceutically acceptable salts thereof. The invention provides methods for (a) treating skin cancer; (b) treating cancer of the organs; (c) treating leukemia; (d) improving the efficacy of chemotherapy, radiation therapy and/or cancer immunotherapy; (e) treating rosacea; and (f) treating psoriasis by administration of a composition comprising at least one 2,5-dihydroxybenzene sulfonic acid compound or a pharmaceutically acceptable salt thereof, and, optionally at least one therapeutic agent. Also disclosed are compositions comprising administration of at least one 2,5-dihydroxybenzene sulfonic acid compound, or a pharmaceutically acceptable salt thereof, and, at least one therapeutic agent. In the invention the 2,5-dihydroxybenzene sulfonic acid compounds or pharmaceutically acceptable salts thereof are 2,5-dihydroxybenzene sulfonic acid, calcium 2,5-dihydroxybenzenesulfonate, potassium 2,5-dihydroxybenzenesulfonate, magnesium 2,5-dihydroxybenzenesulfonate and diethylamine 2,5-dihydroxybenzenesulfonate. | 03-05-2015 |
514711000 | Acyclic | 8 |
20100087546 | USE OF DIMETHYL SULFONE (MSM) TO REDUCE HOMOCYSTEINE LEVELS - A method for reducing elevated levels of homocysteine in a subject comprising the steps of measuring the level of homocysteine in a subject; detecting an elevated level of homocysteine in the subject; and responsive to said step of detecting, administering to said subject a nutritional supplement comprising dimethyl sulfone (MSM). | 04-08-2010 |
20110054039 | USE OF ALKYL SULFATES OR SULFONATES AGAINST PROPIONIBACTERIUM ACNES - An alkyl sulphate or sulphonate having a carbon chain length of 11 or greater, for use in the treatment of a condition which is caused by, transmitted by and/or exacerbated by propionibacterial activity, in particular acne. | 03-03-2011 |
20110105623 | USE OF METHYLSULFONYLMETHANE (MSM) TO MODULATE MICROBIAL ACTIVITY - Disclosed herein are methods of use of methylsulfonylmethane (MSM) to modulate microbial activity, such as to enhance or inhibit the activity of microorganisms. In one example, MSM (such as about 0.5% to 5% MSM) is used to enhance fermentation efficiency, such as to enhance fermentation efficiency associated with the production of beer, cider, wine, a biofuel, dairy product or any combination thereof. Also disclosed are in vitro methods for enhancing the growth of one or more probiotic microorganisms and methods of enhancing growth of a microorganism in a diagnostic test sample. Methods of inhibiting microbial activity are also disclosed. In one particular example, a method of inhibiting microbial activity includes selecting a medium that is susceptible to H1N1 influenza contamination; and contacting the medium with MSM at a concentration of about 10% to about 16% of weight by volume, thereby inhibiting H1N1 influenza microbial activity. | 05-05-2011 |
20120220667 | USE OF METHYLSULFONYLMETHANE (MSM) TO INHIBIT MICROBIAL ACTIVITY - Disclosed herein are methods of use of methylsulfonylmethane (MSM) to modulate microbial activity, such as to enhance or inhibit the activity of microorganisms. In one example, MSM (such as about 0.5% to 5% MSM) is used to enhance fermentation efficiency, such as to enhance fermentation efficiency associated with the production of beer, cider, wine, a biofuel, dairy product or any combination thereof. Also disclosed are in vitro methods for enhancing the growth of one or more probiotic microorganisms and methods of enhancing growth of a microorganism in a diagnostic test sample. Methods of inhibiting microbial activity are also disclosed. In one particular example, a method of inhibiting microbial activity includes selecting a medium that is susceptible to H1N1 influenza contamination; and contacting the medium with MSM at a concentration of about 10% to about 16% of weight by volume, thereby inhibiting H1N1 influenza microbial activity. | 08-30-2012 |
20130065967 | USE OF METHYLSULFONYLMETHANE (MSM) TO INHIBIT MICROBIAL ACTIVITY - Disclosed herein are methods of use of methylsulfonylmethane (MSM) to modulate microbial activity, such as to enhance or inhibit the activity of microorganisms. In one example, MSM (such as about 0.5% to 5% MSM) is used to enhance fermentation efficiency, such as to enhance fermentation efficiency associated with the production of beer, cider, wine, a biofuel, dairy product or any combination thereof. Also disclosed are in vitro methods for enhancing the growth of one or more probiotic microorganisms and methods of enhancing growth of a microorganism in a diagnostic test sample. Methods of inhibiting microbial activity are also disclosed. In one particular example, a method of inhibiting microbial activity includes selecting a medium that is susceptible to H1N1 influenza contamination; and contacting the medium with MSM at a concentration of about 10% to about 16% of weight by volume, thereby inhibiting H1N1 influenza microbial activity. | 03-14-2013 |
20150105473 | AN ANTIBACTERIAL COMPOSITION WITH LOW AMOUNTS OF SURFACTANT AND ANTIBACTERIAL ACTIVES - An antibacterial composition includes at least one surfactant that is less than 6.0 weight percent of the composition and at least one antibacterial active that is less than 0.2 weight percent of the composition. The composition also has a pH between 6.0 and 6.5. The composition also exhibits an efficacy characteristic that results in a logarithmic reduction of at least 2.0 of a bacterial population based on measurements taken from of a user's hand. | 04-16-2015 |
20160045452 | SODIUM TETRADECYL SULFATE FORMULATIONS FOR TREATMENT OF ADIPOSE TISSUE - Contained herein are compositions, formulations, methods, and kits for treating regional fat deposits and fat-related conditions. Certain methods comprise administering tetradecyl sulfate, tetradecyl sulfate-like compounds, and pharmaceutically or cosmetically acceptable salts, solvates, prodrugs, or esters thereof and a liquid carrier. | 02-18-2016 |
20190142764 | METHODS FOR TREATMENT OF INTERSTITIAL CYSTITIS | 05-16-2019 |
514712000 | Thioether | 4 |
20100204338 | ANTI-ANGIOGENIC AGENTS AND METHODS OF USE - The present disclosure relates generally to treating or preventing diseases associated with angiogenesis by administering to a patient certain compounds found to inhibit or substantially reduce angiogenesis. Compounds employed according to the present disclosure exhibit good anti-angiogenic activity as well as demonstrate a prophylactic effect for preventing and substantially reducing angiogenesis. Examples of such compounds include Ritanserin, Amiodarone, Terfenadinc, Perphenazine, Bithionol, and Clomipramine. | 08-12-2010 |
20110196045 | ESTROGENIC COMPOUNDS, PROCESS FOR THEIR PRODUCTION AND PHARMACEUTICAL USES THEREOF - The present invention provides new estrogenic compounds of the general formula | 08-11-2011 |
20130274344 | ESTROGENIC COMPOUNDS, PROCESS FOR THEIR PRODUCTION AND PHARMACEUTICAL USES THEREOF - The presently disclosed and claimed inventive concept(s) provides new estrogenic compounds of the general formula | 10-17-2013 |
20140155493 | BIS-AROMATIC ANTICANCER AGENTS - Treatment of cancer includes administering a compound of formula (I) to a subject. In particular, treatment of colorectal cancer is described. | 06-05-2014 |